Summit Therapeutics and Revolution Medicines Partner to Develop Cancer Therapies

A Clinical Collaboration to Fuel the Healthcare Market

Image Credits: Seeking Alpha

Announcement

Summit Therapeutics Inc., a biopharmaceutical oncology company, and Revolution Medicines Inc., a leading clinical oncology company, have entered into a clinical collaboration. Revolution medicines mainly focus on providing therapies for RAS-addicted cancer patients. Whereas, Summit Therapeutics develops patient-friendly medicinal therapies. The collaboration initiates understanding of various solid tumor settings to evaluate the efficacy and safety of Revolution medicines' clinical-stage RAS (ON) inhibitor, also adding G12D-selective inhibitor zoldonrasib (RMC-9805), G12C-selective inhibitor elironrasib (RMC-6291), and multi-selective inhibitor daraxonrasib (RMC-6236), further compiling with Summit Therapeutics’ PD-1/VEGF bispecific antibody (Ivonescimab).

Collaboration

The collaboration is initiated to achieve clinical factors and receive validation for the compilation of drugs. The combination of the three priority tumor types consists of colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and RAS mutant non-small cell lung cancer (NSCLC). The agreement’s terms and conditions imply that the supply of Ivonescimab will be initiated by Summit Therapeutics for clinical research, and Revolution Medicines will be a study sponsor for the clinical trials. Both companies will have possession of commercial rights regarding the compounds. The agreement is mutually inclusive. The agreement equally divides roles and responsibilities to develop and introduce innovation to the vast healthcare market. An effective study needs accessibility and availability for a smooth outcome. The sponsorship of the Summit Therapeutics to initiate trials will focus on the development and solutions for the healthcare sector.

Views and Statements

Chairman and Chief Executive Officer of Revolution Medicines, MD, Phd, Mark A. Goldsmith said, “We’ve opened up the potential and initial evidence that both elironrasi and daraxonrasib can provide additive antitumor activity by combining PD-1 antibody in first-line treatment with RAS mutant non-small cell lung cancer to patients.” Further, “The compilation with novel PD-1 bispecific inhibitors can discover the next level therapeutic potential. We are looking forward to evaluating combinations of investigational drugs from the company’s RAS (ON) inhibitor portfolio with ivonescimab. It’s an advanced PD-1/VEGF bispecific inhibitor with a unique profile that includes common RAS mutant cancers.”

Chairman and Co-Chief Executive Officer, Robert W. Duggan, and President and Co-Chief Executive Officer of Summit Therapeutics, Dr. Maky Zanganeh, said, “We’re excited to partner with Revolution medicines to evaluate a clinical setting and addressing the potential of the new combination for enhancing the outcome for patients suffering from lung and gastrointestinal cancers.” Further, “We continue to advance the clinical development of ivonescimab in solid tumors and non-small cell lung cancer. This innovative therapy option is important for patients.”